文献速递胸部肿瘤

信迪利单抗联合贝伐珠单抗生物类似药IBI305及化疗用于EGFR突变非鳞非小细胞肺癌EGFR酪氨酸激酶抑制剂治疗进展患者(ORIENT-31):随机双盲多中心3期试验首次中期结果

Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2022-07-28

ORIENT-31研究在中国52家医院纳入444例EGFR-TKI进展的EGFR突变非鳞NSCLC患者,随机接受信迪利单抗+IBI305+化疗、信迪利单抗+化疗或单纯化疗。首次中期分析显示信迪利单抗+IBI305+化疗组中位PFS 6.9个月,显著优于单纯化疗组4.3个月(HR 0.46,P<0.0001),总体耐受性良好。

要点

  • 信迪利单抗+IBI305+化疗组中位PFS 6.9个月 vs 单纯化疗组4.3个月,HR 0.46(95%CI 0.34-0.64),P<0.0001
  • 信迪利单抗+化疗组PFS数据尚不成熟,本次未报告
  • 信迪利单抗+IBI305+化疗组报告6例可能治疗相关死亡,单纯化疗组1例

核心结论

  • 本次中期分析中,信迪利单抗联合IBI305及顺铂和培美曲塞在EGFR-TKI治疗进展的EGFR突变NSCLC患者中总体有效且耐受性良好。

研究设计与样本

  • 随机、双盲、多中心3期试验,在中国52家医院开展。
  • 纳入18-75岁局部晚期或转移性EGFR突变NSCLC、EGFR-TKI治疗后进展、ECOG PS 0或1、至少一个可测量病灶、预期生存至少3个月的患者。
  • 共筛查936例,随机分配444例:信迪利单抗+IBI305+化疗组148例,信迪利单抗+化疗组145例,单纯化疗组151例。
  • 所有研究药物静脉给药,每3周第1天一次;顺铂仅前4周期给予,其他药物给药24个月或直至疾病进展、不可耐受毒性、撤回知情同意、死亡或其他方案规定情况。
  • 主要终点为意向治疗人群的无进展生存期(PFS);本次报告首次计划中期分析中信迪利单抗+IBI305+化疗组 vs 单纯化疗组的PFS结果,信迪利单抗+化疗组PFS数据不成熟未报告。

主要发现

  • 中位随访9.8个月(IQR 4.4-13.3),信迪利单抗+IBI305+化疗组中位PFS 6.9个月(95%CI 6.0-9.3)vs 单纯化疗组4.3个月(95%CI 4.1-5.4),HR 0.46(95%CI 0.34-0.64),P<0.0001。
  • 最常见的3或4级治疗相关不良事件为中性粒细胞计数降低:信迪利单抗+IBI305+化疗组30例(20%)vs 信迪利单抗+化疗组26例(18%)vs 单纯化疗组27例(18%)。
  • 白细胞计数降低:信迪利单抗+IBI305+化疗组17例(11%)vs 信迪利单抗+化疗组12例(8%)vs 单纯化疗组13例(9%)。
  • 贫血:信迪利单抗+IBI305+化疗组18例(12%)vs 信迪利单抗+化疗组10例(7%)vs 单纯化疗组15例(10%)。
  • 可能治疗相关死亡:信迪利单抗+IBI305+化疗组6例(肠梗阻、消化道出血、骨髓抑制各1例,不明原因3例),单纯化疗组1例(不明原因)。

局限性

  • 信迪利单抗+化疗组的PFS结果尚不成熟,本次未报告。
  • 本研究为首次计划中期分析,报告的是信迪利单抗+IBI305+化疗组 vs 单纯化疗组的PFS比较结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: VEGF inhibitors can enhance the efficacy of immunotherapy. However, despite high initial response rates, almost all patients eventually develop treatment resistance to EGFR tyrosine-kinase inhibitors. We aimed to evaluate the efficacy and safety of sintilimab with or without IBI305 plus pemetrexed and cisplatin, compared with pemetrexed and cisplatin alone, for the treatment of patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) who had disease progression after receiving EGFR tyrosine-kinase inhibitor therapy. METHODS: This randomised, double-blind, multicentre, phase 3 trial was conducted at 52 hospitals in China. Eligible participants were adults aged 18-75 years with locally advanced or metastatic NSCLC and EGFRmut who progressed after receiving a EGFR tyrosine-kinase inhibitor, had an Eastern Cooperative Oncology Group performance status of 0 or 1 with at least one measurable lesion, and an estimated life expectancy of at least 3 months. Participants were randomly assigned (1:1:1) to receive sintilimab (200 mg) plus IBI305 (15 mg/kg) plus pemetrexed (500 mg/m2) and cisplatin (75 mg/m2), sintilimab plus pemetrexed and cisplatin, or pemetrexed and cisplatin (chemotherapy alone) using block randomisation with stratification according to sex and presence or absence of brain metastases. All study drugs were administered intravenously on day 1 of each cycle, once every 3 weeks. Except for cisplatin, which was only given in the first four cycles, treatment was given for 24 months or until disease progression, intolerable toxic effects, withdrawal of consent, death, or other protocol-specified conditions, whichever occurred first. The primary endpoint was progression-free survival in the intention-to-treat population. We herein report the first planned interim analysis, with progression-free survival results for the comparison between sintilimab plus IBI305 plus chemotherapy versus chemotherapy alone. The progression-free survival results for the sintilimab plus pemetrexed and cisplatin group are immature and not reported here. This study is registered with ClinicalTrials.gov, NCT03802240 (recruiting). FINDINGS: Between July 11, 2019, and July 31, 2021, 936 patients were screened and 444 were randomly assigned (148 to the sintilimab plus IBI305 plus chemotherapy group, 145 to the sintilimab plus chemotherapy group, and 151 to the chemotherapy alone group). Data cutoff for this interim analysis was July 31, 2021. After a median follow-up of 9·8 months (IQR 4·4-13·3), progression-free survival was significantly longer in the sintilimab plus IBI305 plus chemotherapy group versus the chemotherapy alone group (median 6·9 months [95% CI 6·0-9.3] vs 4·3 months [4·1-5·4]; hazard ratio 0·46 [0·34-0·64]; p<0·0001). The most common grade 3 or 4 treatment-related adverse events were decreased neutrophil count (30 [20%] in the sintilimab plus IBI305 plus chemotherapy group vs 26 [18%] in the sintilimab plus chemotherapy group vs 27 [18%] in the chemotherapy alone group), decreased white blood cell count (17 [11%] vs 12 [8%] vs 13 [9%]), and anaemia (18 [12%] vs ten [7%] vs 15 [10%]). Potentially treatment-related deaths occurred in six patients (intestinal obstruction, gastrointestinal haemorrhage, and myelosuppression in one patient each, and three deaths of unknown cause) in the sintilimab plus IBI305 plus chemotherapy group, and in one patient in the chemotherapy alone group (unknown cause). INTERPRETATION: In this interim analysis, sintilimab plus IBI305 plus cisplatin and pemetrexed was generally efficacious and well tolerated in patients with EGFR-mutated NSCLC who progressed after receiving EGFR tyrosine-kinase inhibitor therapy. FUNDING: Innovent Biologics and the National Natural Science Foundation of China. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Lu S, Wu L, Jian H, et al. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2022. PMID: 35908558. doi:10.1016/S1470-2045(22)00382-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。